Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15-18 Months of Age Among Human Immunodeficiency Virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed Children.
HIV
HIV exposure
antibody response
measles vaccine
persistence
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
received:
18
09
2018
accepted:
08
11
2018
pubmed:
13
11
2018
medline:
17
6
2020
entrez:
13
11
2018
Statut:
ppublish
Résumé
Human immunodeficiency virus (HIV)-infected and HIV-exposed-uninfected (HEU) children may be at increased risk of measles infection due to waning of immunity following vaccination. We evaluated persistence of antibodies to measles vaccination at 4.5 years of age in HIV-unexposed, HEU, and HIV-infected children with CD4+ ≥25% previously randomized to immediate antiretroviral therapy (ART) interrupted at 12 months (HIV/Immed-ART-12), 24 months (HIV/Immed-ART-24), or when clinically/immunologically indicated (HIV/Def-ART). The HIV/Def-ART group initiated ART by median 5.8 (interquartile range, 4.4-10.3) months of age. In this study, HIV-unexposed (n = 95), HEU (n = 84), HIV/Immed-ART-12 (n = 70), HIV/Immed-ART-24 (n = 70), and HIV/Def-ART (n = 62) children were scheduled to receive measles vaccination at age 9 and 15-18 months. Antimeasles serum immunoglobulin G titers were quantified using enzyme-linked immunosorbent assay at 4.5 years. Compared with HIV-unexposed children (2860 mIU/mL), measles antibody geometric mean titers (GMTs) were significantly lower in both HIV/Immed-ART-12 (571; P < .001) and HIV/Immed-ART-24 (1136; P < .001) but similar in the HIV/Def-ART (2777) and HEU (3242) groups. Furthermore, compared with HIV-unexposed, antibody titers ≥330 mIU/mL (ie, presumed serocorrelate for protection; 99%) were also significantly lower in HIV/Immed-ART-12 (70%; P < .001) and HIV/Immed-ART-24 (83%; P < .001) but similar in the HIV/Def-ART (90%) and HEU (98%) groups. HIV-infected children in whom ART was interrupted at either 12 or 24 months had lower GMTs and lower proportions with seroprotective titers than HIV-unexposed children, indicating a potential downside of ART treatment interruption. NCT00099658 and NCT00102960.
Sections du résumé
BACKGROUND
Human immunodeficiency virus (HIV)-infected and HIV-exposed-uninfected (HEU) children may be at increased risk of measles infection due to waning of immunity following vaccination. We evaluated persistence of antibodies to measles vaccination at 4.5 years of age in HIV-unexposed, HEU, and HIV-infected children with CD4+ ≥25% previously randomized to immediate antiretroviral therapy (ART) interrupted at 12 months (HIV/Immed-ART-12), 24 months (HIV/Immed-ART-24), or when clinically/immunologically indicated (HIV/Def-ART). The HIV/Def-ART group initiated ART by median 5.8 (interquartile range, 4.4-10.3) months of age.
METHODS
In this study, HIV-unexposed (n = 95), HEU (n = 84), HIV/Immed-ART-12 (n = 70), HIV/Immed-ART-24 (n = 70), and HIV/Def-ART (n = 62) children were scheduled to receive measles vaccination at age 9 and 15-18 months. Antimeasles serum immunoglobulin G titers were quantified using enzyme-linked immunosorbent assay at 4.5 years.
RESULTS
Compared with HIV-unexposed children (2860 mIU/mL), measles antibody geometric mean titers (GMTs) were significantly lower in both HIV/Immed-ART-12 (571; P < .001) and HIV/Immed-ART-24 (1136; P < .001) but similar in the HIV/Def-ART (2777) and HEU (3242) groups. Furthermore, compared with HIV-unexposed, antibody titers ≥330 mIU/mL (ie, presumed serocorrelate for protection; 99%) were also significantly lower in HIV/Immed-ART-12 (70%; P < .001) and HIV/Immed-ART-24 (83%; P < .001) but similar in the HIV/Def-ART (90%) and HEU (98%) groups.
CONCLUSIONS
HIV-infected children in whom ART was interrupted at either 12 or 24 months had lower GMTs and lower proportions with seroprotective titers than HIV-unexposed children, indicating a potential downside of ART treatment interruption.
CLINICAL TRIALS REGISTRATION
NCT00099658 and NCT00102960.
Identifiants
pubmed: 30418528
pii: 5174340
doi: 10.1093/cid/ciy964
pmc: PMC6669279
doi:
Substances chimiques
Anti-Retroviral Agents
0
Antibodies, Viral
0
Measles Vaccine
0
Banques de données
ClinicalTrials.gov
['NCT00099658', 'NCT00102960']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
687-696Subventions
Organisme : NIAID NIH HHS
ID : HHSN272200800014C
Pays : United States
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Infect Dis. 2010 Aug 15;202(3):355-61
pubmed: 20583920
AIDS. 2014 Jun 19;28(10):1421-30
pubmed: 24785950
S Afr Med J. 2012 Aug 22;102(9):760-4
pubmed: 22958701
Immunol Rev. 2017 Jan;275(1):33-48
pubmed: 28133792
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
BMJ. 2010 May 18;340:c1626
pubmed: 20483946
Pediatrics. 2003 Jun;111(6 Pt 1):e641-4
pubmed: 12777579
Clin Vaccine Immunol. 2013 Jan;20(1):33-8
pubmed: 23114697
J Infect Dis. 2007 Aug 1;196(3):347-55
pubmed: 17597448
AIDS. 2005 Jul 1;19(10):1071-9
pubmed: 15958839
Clin Exp Immunol. 2007 Sep;149(3):430-9
pubmed: 17511776
Front Immunol. 2016 Sep 28;7:383
pubmed: 27733852
Clin Vaccine Immunol. 2011 Sep;18(9):1406-9
pubmed: 21775515
BMC Infect Dis. 2011 Feb 03;11:38
pubmed: 21291536
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7939-44
pubmed: 19416836
Southeast Asian J Trop Med Public Health. 2000 Dec;31(4):658-62
pubmed: 11414407
Wkly Epidemiol Rec. ;92(17):205-27
pubmed: 28459148
World Health Organ Tech Rep Ser. 1964;293:1-86
pubmed: 14266794
Clin Vaccine Immunol. 2016 Jul 05;23(7):576-85
pubmed: 27170641
J Infect Dis. 2008 Nov 15;198(10):1457-65
pubmed: 18828743
Clin Immunol. 2008 Jun;127(3):340-7
pubmed: 18356112
AIDS. 2013 Jun 19;27(10):1583-91
pubmed: 24047763
PLoS One. 2013;8(2):e55682
pubmed: 23437059
JAMA. 2011 Feb 9;305(6):576-84
pubmed: 21304083
AIDS. 2014 Feb 20;28(4):531-41
pubmed: 24468996
BMC Public Health. 2013 Jul 01;13:619
pubmed: 23816281
N Engl J Med. 2008 Nov 20;359(21):2233-44
pubmed: 19020325
Pediatr Infect Dis J. 2018 Apr;37(4):304-309
pubmed: 29140938
J Infect Dis. 1990 Nov;162(5):1036-42
pubmed: 2230231
Lancet. 1999 Jan 9;353(9147):98-102
pubmed: 10023894
EClinicalMedicine. 2018 Jul 02;1:28-42
pubmed: 31193646
Bull World Health Organ. 2013 Mar 1;91(3):174-83
pubmed: 23476090
J Infect Dis. 2011 Jul;204 Suppl 1:S149-57
pubmed: 21666156
Pediatrics. 2006 Aug;118(2):e315-22
pubmed: 16847077
Trop Med Int Health. 2009 Mar;14(3):276-87
pubmed: 19171011
Clin Infect Dis. 2014 Apr;58(8):1130-9
pubmed: 24415637
J Clin Virol. 2007 Mar;38(3):204-9
pubmed: 17289430
Lancet. 2013 Nov 9;382(9904):1555-63
pubmed: 24209829